Cargando…
Effects of secretome on cisplatin-induced testicular dysfunction in rats
BACKGROUND: Testicular dysfunction is a degenerative disorder characterized by failure in the synthesis of reproductive hormones and spermatogenesis. Secretome derived from the human umbilical mesenchymal stem cell (MSC) has been reported to repair some degenerative disorders. AIM: This study aimed...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Veterinary World
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200560/ https://www.ncbi.nlm.nih.gov/pubmed/30410245 http://dx.doi.org/10.14202/vetworld.2018.1349-1356 |
_version_ | 1783365353820127232 |
---|---|
author | Prihatno, Surya Agus Padeta, Irma Larasati, Arinda Devi Sundari, Betty Hidayati, Annisa Fibrianto, Yuda Heru Budipitojo, Teguh |
author_facet | Prihatno, Surya Agus Padeta, Irma Larasati, Arinda Devi Sundari, Betty Hidayati, Annisa Fibrianto, Yuda Heru Budipitojo, Teguh |
author_sort | Prihatno, Surya Agus |
collection | PubMed |
description | BACKGROUND: Testicular dysfunction is a degenerative disorder characterized by failure in the synthesis of reproductive hormones and spermatogenesis. Secretome derived from the human umbilical mesenchymal stem cell (MSC) has been reported to repair some degenerative disorders. AIM: This study aimed to investigate the effect of secretome derived from the human umbilical MSCs on cisplatin-induced testicular dysfunction in rats. MATERIALS AND METHODS: Thirty-six male Wistar rats were divided into the control and secretome-treated groups. In the secretome-treated group, testicular dysfunction was induced by 3 mg/kg BW of cisplatin intraperitoneally 3 times with 3-day intervals. The secretome-treated group was divided according to dose: Low-dose (0.2 mL/kg BW) and high-dose (0.5 mL/kg BW) groups. Secretomes were injected intraperitoneally once a week for 3 weeks. 1 week after the injection of secretome, the cauda epididymis of the rats was removed for spermatozoa evaluation and histological examination. RESULT: After the injection of secretome, the sperm motility of the high-dose group showed thin wave-like, rare, and slow movements. No abnormal sperm morphology was observed in all the treated groups. The number of spermatozoa increased gradually in the high-dose group after the injection of secretome. The developmental stages of the spermatogenic cells were complete in both spermatozoa groups after the injection of secretome. However, the spermatozoa in the seminiferous tubules of the high-dose group were denser. Vimentin and cytokeratin immunoreactivities were very strong in the high-dose group 1 week after the second secretome injection. CONCLUSION: High-dose secretome derived from the human fetal umbilical cord could increase the number and motility of sperms in rats with cisplatin-induced testicular dysfunction. The administration of high-dose secretome was effective 1 week after the second dose, as indicated by very strong immunoreactivity for vimentin and cytokeratin. Moreover, secretome could promote the regeneration of the seminiferous tubules of both the groups. |
format | Online Article Text |
id | pubmed-6200560 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Veterinary World |
record_format | MEDLINE/PubMed |
spelling | pubmed-62005602018-11-08 Effects of secretome on cisplatin-induced testicular dysfunction in rats Prihatno, Surya Agus Padeta, Irma Larasati, Arinda Devi Sundari, Betty Hidayati, Annisa Fibrianto, Yuda Heru Budipitojo, Teguh Vet World Research Article BACKGROUND: Testicular dysfunction is a degenerative disorder characterized by failure in the synthesis of reproductive hormones and spermatogenesis. Secretome derived from the human umbilical mesenchymal stem cell (MSC) has been reported to repair some degenerative disorders. AIM: This study aimed to investigate the effect of secretome derived from the human umbilical MSCs on cisplatin-induced testicular dysfunction in rats. MATERIALS AND METHODS: Thirty-six male Wistar rats were divided into the control and secretome-treated groups. In the secretome-treated group, testicular dysfunction was induced by 3 mg/kg BW of cisplatin intraperitoneally 3 times with 3-day intervals. The secretome-treated group was divided according to dose: Low-dose (0.2 mL/kg BW) and high-dose (0.5 mL/kg BW) groups. Secretomes were injected intraperitoneally once a week for 3 weeks. 1 week after the injection of secretome, the cauda epididymis of the rats was removed for spermatozoa evaluation and histological examination. RESULT: After the injection of secretome, the sperm motility of the high-dose group showed thin wave-like, rare, and slow movements. No abnormal sperm morphology was observed in all the treated groups. The number of spermatozoa increased gradually in the high-dose group after the injection of secretome. The developmental stages of the spermatogenic cells were complete in both spermatozoa groups after the injection of secretome. However, the spermatozoa in the seminiferous tubules of the high-dose group were denser. Vimentin and cytokeratin immunoreactivities were very strong in the high-dose group 1 week after the second secretome injection. CONCLUSION: High-dose secretome derived from the human fetal umbilical cord could increase the number and motility of sperms in rats with cisplatin-induced testicular dysfunction. The administration of high-dose secretome was effective 1 week after the second dose, as indicated by very strong immunoreactivity for vimentin and cytokeratin. Moreover, secretome could promote the regeneration of the seminiferous tubules of both the groups. Veterinary World 2018-09 2018-09-29 /pmc/articles/PMC6200560/ /pubmed/30410245 http://dx.doi.org/10.14202/vetworld.2018.1349-1356 Text en Copyright: © Prihatno, et al. http://creativecommons.org/licenses/by/4.0 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Prihatno, Surya Agus Padeta, Irma Larasati, Arinda Devi Sundari, Betty Hidayati, Annisa Fibrianto, Yuda Heru Budipitojo, Teguh Effects of secretome on cisplatin-induced testicular dysfunction in rats |
title | Effects of secretome on cisplatin-induced testicular dysfunction in rats |
title_full | Effects of secretome on cisplatin-induced testicular dysfunction in rats |
title_fullStr | Effects of secretome on cisplatin-induced testicular dysfunction in rats |
title_full_unstemmed | Effects of secretome on cisplatin-induced testicular dysfunction in rats |
title_short | Effects of secretome on cisplatin-induced testicular dysfunction in rats |
title_sort | effects of secretome on cisplatin-induced testicular dysfunction in rats |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200560/ https://www.ncbi.nlm.nih.gov/pubmed/30410245 http://dx.doi.org/10.14202/vetworld.2018.1349-1356 |
work_keys_str_mv | AT prihatnosuryaagus effectsofsecretomeoncisplatininducedtesticulardysfunctioninrats AT padetairma effectsofsecretomeoncisplatininducedtesticulardysfunctioninrats AT larasatiarindadevi effectsofsecretomeoncisplatininducedtesticulardysfunctioninrats AT sundaribetty effectsofsecretomeoncisplatininducedtesticulardysfunctioninrats AT hidayatiannisa effectsofsecretomeoncisplatininducedtesticulardysfunctioninrats AT fibriantoyudaheru effectsofsecretomeoncisplatininducedtesticulardysfunctioninrats AT budipitojoteguh effectsofsecretomeoncisplatininducedtesticulardysfunctioninrats |